Pharmaceuticals & Vitamin D
Vitamin D Analog “AB-47” for Cancer Prevention and Treatment
Inventors: Hector DeLuca, Rafal Barycki, Lori Plum
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a vitamin D analog that is potentially useful as a chemotherapeutic agent, particularly against leukemia and lung cancer.
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for non-calcemic compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.
UW–Madison researchers have developed a novel vitamin D analog, 22-bromoacetoxy-homopregnacalciferol, also known as AB-47. This analog binds the vitamin D receptor with much lower affinity than the native hormone, has very low ability to stimulate gene transcription and has little calcemic activity. AB-47 does not promote cancer cell differentiation. Instead, it has been shown to kill cancer cells in a leukemia cell line as well as in small cell lung carcinoma, making it potentially useful for the treatment of some types of cancer.
- Cancer treatment, particularly for leukemia or lung cancer
- Kills certain types of cancer cells without deleterious side effects
- Less likely to cause dose-limiting hypercalcemia than calcitriol
- Can be administered in many forms
For More Information About the Inventors